Free Newsletter
FDA: Eisai drug increases acidosis risk
The FDA warned doctors that Eisai's epilepsy drug Zonegran can cause a metabolic disorder--acidosis--that can increase the risk of kidney stones and bone disease; the drug's label will be updated accordingly, the agency said. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: